Results 191 to 200 of about 1,442,988 (353)

Recombinant bispecific antibodies for cancer therapy [PDF]

, 2005
Roland E. Kontermann
openalex   +1 more source

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

Recombinant approaches to IgG-like bispecific antibodies [PDF]

, 2005
Jonathan S. Marvin, Zhenping Zhu
openalex   +1 more source

Bispecific Antibodies and Gene Therapy

, 2011
Gene therapy is the transfer of therapeutic genes, via gene transfer vectors, into patients for therapeutic purposes. Different gene therapy strategies are being pursued, including long-term gene correction of monogenetic diseases, eradication of tumor cells in cancer patients, or genetic vaccination for infectious diseases.
openaire   +2 more sources

The dark sides of the GPCR tree ‐ research progress on understudied GPCRs

British Journal of Pharmacology, EarlyView.
Abstract A large portion of the human GPCRome is still in the dark and understudied, consisting even of entire subfamilies of GPCRs such as odorant receptors, class A and C orphans, adhesion GPCRs, Frizzleds and taste receptors. However, it is undeniable that these GPCRs bring an untapped therapeutic potential that should be explored further.
Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, Antonella Di Pizio, Juliane Lehmann, Ines Liebscher, Alessandro Nicoli, Masha Y. Niv, Lior Peri, Hannes Schihada, Gunnar Schulte   +10 more
wiley   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Composite Lymphoma: A Rare Case of Vomiting

United European Gastroenterology Journal, EarlyView.
Changqin Liu, Dongyan Han, Xiaomin Sun
wiley   +1 more source

Opportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy

Cancer Science, EarlyView.
There remain outstanding gaps between the negative results from clinical trials and the actual potential of the immune system for glioblastoma. To bridge this crucial gap, we collaborated with Dr. Mariko Takahashi, an expert in immunobiology and drug development, and Dr. James J.
Mariko Takahashi, Darina Mukhamejanova, Himani Jasewicz, Nandini Acharya, James J. Moon, Toshiro Hara   +5 more
wiley   +1 more source

Characteristics of second primary malignancies following bispecific antibodies therapy. [PDF]

J Immunother Cancer
Liang X, Luo B, Lin B, Liu D, Guo J, Lu W, Tian S, Cai Z, Zhou X, Jin Z, Li T, Chen K, Zhou H, Wang L.   +13 more
europepmc   +1 more source

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

, 2001
Christoph Renner, Ingo Stehle, Fook Thean Lee, Cathrine Hall, Bruno Catimel, Edouard C. Nice, Angela Mountain, Angela Rigopoulos, Martin W. Brechbiel, M. Pfreundschuh, Andrew M. Scott   +10 more
openalex   +1 more source